Listen
Reason for request
Inclusion
-
Clinical Benefit
| Substantial |
The actual benefit of XALUPRINE is substantial in the MarketingAuthorisation indication. |
Clinical Added Value
| minor |
XALUPRINE provides a minor improvement in actual benefit (IAB IV) compared with mercaptopurine in tablet form in the treatment of acute lymphoblastic leukaemia in children (paediatric population). |
| no clinical added value |
In adults and adolescents, XALUPRINE does not provide any improvement in actual benefit (IAB V, non-existent)compared with mercaptopurine in tablet form in the treatment of acute lymphoblastic leukaemia. |
